Stryker (SYK) Q2 FY26 earnings call

Stryker delivered robust Q2 FY26 results, demonstrating resilience in recovering from the Q1 cybersecurity incident with 9% organic sales growth and 17.9% adjusted EPS growth. The company is experiencing strong demand for capital products, leading to an elevated backlog, and expects continued momentum in the second half. Despite a supply disruption in Peripheral Vascular, management is confident in its ability to meet narrowed full-year guidance and resume share repurchases.